RxDoctor Payments Data

Cuicui Zhang, APRN

Addiction Medicine · Sandy, UTNPI 1518516210

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 93.5% of the total across 75 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AbbVie at 37.5% of the total. 2025 is the largest year on record at $674, more than ten times the $23 reported in 2021.

$1,297in general payments, 2019–2025

Across 75 payments — averaging $17.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$487
  • Vanda Pharmaceuticals Inc.$125
  • Indivior Inc.$111
  • Braeburn Inc.$107
  • Gilead$83
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$66
  • plus $319 from 14 others

What the payments were for

  • Food & beverage$1,21393%
  • Education$857%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,297 in reported general payments places this provider in the 75th percentile of 21 addiction medicine providers in Utah.

See all addiction medicine providers in Utah

Medicare billing

Part B allowed, 2024
$20,601
Medicare patients
44
Services billed
457

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide14$14,464
Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine47$1,552
Buprenorphine Hcl17$846
Dextroamphetamine-Amphet ErDextroamphetamine/Amphetamine12$565
Clonazepam34$560
Gabapentin46$543
Quetiapine Fumarate13$460
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen18$406
Albuterol Sulfate HfaAlbuterol Sulfate18$266
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen15$261
Trazodone Hcl11$201
Omeprazole11$193
Ondansetron OdtOndansetron19$156
Atorvastatin Calcium13$98
Oxycodone Hcl11$98

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$14$14,46414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 21 addiction medicine providers in Utah.

Other addiction medicine in Sandy

See the full list for Utah

Where these figures come from

Is this you, or does something look wrong? →